Moderna asks US, European regulators to OK its coronavirus vaccine

Moderna asks US, European regulators to OK its coronavirus
vaccine 1

Moderna
Inc. says it will ask U.S. and European regulators to allow
emergency use of its COVID-19 vaccine as new study results confirm
the shots offer strong protection. | AP file

Moderna is just behind Pfizer and its German partner BioNTech in
seeking to begin vaccinations in the U.S. in December.

Moderna Inc. said it would ask U.S. and European regulators
Monday to allow emergency use of its COVID-19 vaccine as new study
results confirm the shots offer strong protection — ramping up
the race to begin limited vaccinations as the coronavirus rampage
worsens.

Multiple vaccine candidates must succeed for the world to stamp
out the pandemic, which has been on the upswing in the U.S. and
Europe. U.S. hospitals have been stretched to the limit as the
nation has seen more than 160,000 new cases per day and more than
1,400 daily deaths. Since first emerging nearly a year ago in
China, the virus has killed more than 1.4 million people
worldwide.

Moderna is just behind Pfizer and its German partner BioNTech in
seeking to begin vaccinations in the U.S. in December. Across the
Atlantic, British regulators also are assessing the Pfizer shot and
another from AstraZeneca.

Moderna created its shots with the U.S. National Institutes of
Health and already had a hint they were working, but said it got
the final needed results over the weekend that suggest the vaccine
is more than 94% effective.

Price & Product Availability Tracker

Discover where products are available & compare prices

Of 196 COVID-19 cases so far in its huge U.S. study, 185 were
trial participants who received the placebo and 11 who got the real
vaccine. The only people who got severely ill — 30 participants,
including one who died — had received dummy shots, said Dr. Tal
Zaks, the Cambridge, Massachusetts, company’s chief medical
officer.

When he learned the results, “I allowed myself to cry for the
first time,” Zaks told The Associated Press. “We have already,
just in the trial, have already saved lives. Just imagine the
impact then multiplied to the people who can get this
vaccine.”

Moderna said the shots’ effectiveness and a good safety record
so far — with only temporary, flu-like side effects — mean they
meet requirements set by the U.S. Food and Drug Administration for
emergency use before the final-stage testing is complete. The
European Medicines Agency, Europe’s version of FDA, has signaled
it also is open to faster, emergency clearance.

The FDA has pledged that before it decides to roll out any
COVID-19 vaccines, its scientific advisers will publicly debate
whether there’s enough evidence behind each candidate.

First up on Dec. 10, Pfizer and BioNTech will present data
suggesting their vaccine candidate is 95% effective. Moderna said
its turn at this “science court” is expected exactly a week
later, on Dec. 17.

If the FDA allows emergency use, Moderna expects to have 20
million doses ready for the U.S. by year’s end. Recipients will
need two doses, so that’s enough for 10 million people.

Pfizer expects to have 50 million doses globally in December.
Half of them — or enough for 12.5 million people — are
earmarked for the U.S.

This week, a different panel of U.S. experts, established by the
Centers for Disease Control and Prevention, will meet to decide how
initial supplies will be given out. They’re expected to reserve
scarce first doses for health care workers and, if the shots work
well enough in the frail elderly, for residents of long-term care
facilities. As more vaccine gradually becomes available in coming
months, other essential workers and people at highest risk from the
coronavirus would get in line. But enough for the general
population isn’t expected until at least spring.

Outside the U.S., Zaks said significant supplies from Moderna
would be available later, “in the first quarter” of next
year.

“Obviously we are doing everything in our power to increase
the capacity and accelerate the timelines,” he said.

Both Moderna’s and Pfizer’s vaccines are made with the same
technology, using a piece of genetic code for the “spike”
protein that studs the virus. That messenger RNA, or mRNA,
instructs the body to make some harmless spike protein, training
immune cells to recognize it if the real virus eventually comes
along.

Read the Full Article

Prepare Now Before its too Late

Discover where products are available & compare prices

Moderna asks US, European regulators to OK its coronavirus vaccine (LIVE UPDATES)
Builders, labor unions open doors for small contractors

You might also like
Menu